Ella Daly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ella Daly has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Madhukar H. Trivedi
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX
2 shared publications - Augustus John Rush
Duke-NUS Medical School, Singapore
1 shared publication - Benji T. Kurian
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
1 shared publication - Bruce D. Grannemann
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
1 shared publication - Cynthia A. Claassen
Mood Disorders Research Program & Clinic, Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, TX, USA
1 shared publication - Jacqueline K. Gollan
Northwestern University Feinberg School of Medicine, Chicago, IL, USA
1 shared publication
Latest Publications
- 6 December 2011
- Published by Hindawi Limited in Depression and Anxiety
- Vol. 29 (2) , 94-101
What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression?
Objective To evaluate the prevalence of new onset or worsening of anxiety symptoms, as well as their clinical implications, during the first 2 weeks of Selective Serotonin Reuptake Inhibitor (SSRI) pharmacotherapy for depression. Method Adult outpatients with nonpsychotic major depressive disorder were enrolled in an 8‐week acute phase SSRI treatment trial at 15 clinical sites across the United States. Worsening anxiety was defined as a greater than 2‐point increase on the Beck Anxiety Inventory (BAI) between baseline and Week 2. New onset of anxiety symptoms was ascribed when the BAI baseline rating was 0 and the Week 2 value was greater or equal to 2 points on the BAI. Results Overall, after 2 weeks of treatment, 48.8% (98 of 201 participants) reported improvement in anxiety symptoms, 36.3% (73 of 201) reported minimal symptom change, and 14.9% (30 of 201) reported worsening of anxiety symptoms. No association was found between change in anxiety symptoms within the first 2 weeks and change in depressive symptoms or remission at the end of 8 weeks of treatment. For participants with clinically meaningful anxiety symptoms at baseline, however, worsening of anxiety during the first 2 weeks of treatment was associated with worsening depressive symptoms by 8 weeks (P = .054). Conclusions The trajectory of anxiety symptom change early in SSRI treatment is an important indicator of eventual outcome for outpatients with major depression and baseline anxiety symptoms. Depression and Anxiety 0:1–8, 2011.
- 6 December 2011
- Published by Hindawi Limited in Depression and Anxiety
- Vol. 29 (2) , 94-101
What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression?
Objective To evaluate the prevalence of new onset or worsening of anxiety symptoms, as well as their clinical implications, during the first 2 weeks of Selective Serotonin Reuptake Inhibitor (SSRI) pharmacotherapy for depression. Method Adult outpatients with nonpsychotic major depressive disorder were enrolled in an 8‐week acute phase SSRI treatment trial at 15 clinical sites across the United States. Worsening anxiety was defined as a greater than 2‐point increase on the Beck Anxiety Inventory (BAI) between baseline and Week 2. New onset of anxiety symptoms was ascribed when the BAI baseline rating was 0 and the Week 2 value was greater or equal to 2 points on the BAI. Results Overall, after 2 weeks of treatment, 48.8% (98 of 201 participants) reported improvement in anxiety symptoms, 36.3% (73 of 201) reported minimal symptom change, and 14.9% (30 of 201) reported worsening of anxiety symptoms. No association was found between change in anxiety symptoms within the first 2 weeks and change in depressive symptoms or remission at the end of 8 weeks of treatment. For participants with clinically meaningful anxiety symptoms at baseline, however, worsening of anxiety during the first 2 weeks of treatment was associated with worsening depressive symptoms by 8 weeks (P = .054). Conclusions The trajectory of anxiety symptom change early in SSRI treatment is an important indicator of eventual outcome for outpatients with major depression and baseline anxiety symptoms. Depression and Anxiety 0:1–8, 2011.
- Open Access
- 21 January 2009
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 9 (1) , 6
Barriers to implementation of a computerized decision support system for depression: an observational report on lessons learned in "real world" clinical settings
Despite wide promotion, clinical practice guidelines have had limited effect in changing physician behavior. Effective implementation strategies to date have included: multifaceted interventions involving audit and feedback, local consensus processes, marketing; reminder systems, either manual or computerized; and interactive educational meetings. In addition, there is now growing evidence that contextual factors affecting implementation must be addressed such as organizational support (leadership procedures and resources) for the change and strategies to implement and maintain new systems. To examine the feasibility and effectiveness of implementation of a computerized decision support system for depression (CDSS-D) in routine public mental health care in Texas, fifteen study clinicians (thirteen physicians and two advanced nurse practitioners) participated across five sites, accruing over 300 outpatient visits on 168 patients. Issues regarding computer literacy and hardware/software requirements were identified as initial barriers. Clinicians also reported concerns about negative impact on workflow and the potential need for duplication during the transition from paper to electronic systems of medical record keeping. The following narrative report based on observations obtained during the initial testing and use of a CDSS-D in clinical settings further emphasizes the importance of taking into account organizational factors when planning implementation of evidence-based guidelines or decision support within a system.
- 21 January 2009
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 9 (1) , 6
Open AccessBarriers to implementation of a computerized decision support system for depression: an observational report on lessons learned in "real world" clinical settings
Despite wide promotion, clinical practice guidelines have had limited effect in changing physician behavior. Effective implementation strategies to date have included: multifaceted interventions involving audit and feedback, local consensus processes, marketing; reminder systems, either manual or computerized; and interactive educational meetings. In addition, there is now growing evidence that contextual factors affecting implementation must be addressed such as organizational support (leadership procedures and resources) for the change and strategies to implement and maintain new systems. To examine the feasibility and effectiveness of implementation of a computerized decision support system for depression (CDSS-D) in routine public mental health care in Texas, fifteen study clinicians (thirteen physicians and two advanced nurse practitioners) participated across five sites, accruing over 300 outpatient visits on 168 patients. Issues regarding computer literacy and hardware/software requirements were identified as initial barriers. Clinicians also reported concerns about negative impact on workflow and the potential need for duplication during the transition from paper to electronic systems of medical record keeping. The following narrative report based on observations obtained during the initial testing and use of a CDSS-D in clinical settings further emphasizes the importance of taking into account organizational factors when planning implementation of evidence-based guidelines or decision support within a system.
- Open Access
- 1 January 2008
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 3 (6) , 855-867
A review of quetiapine in combination with antidepressant therapy in patients with depression
Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articlesor submit your research for publishing
- 1 January 2008
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 3 (6) , 855-867
Open AccessA review of quetiapine in combination with antidepressant therapy in patients with depression
Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articlesor submit your research for publishing